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Abstract 
Objective: To assess associations between cardiorespiratory fitness (CRF), measured as peak oxygen 
uptake (VO2peak) and cardiovascular disease (CVD) risk, measured by arterial stiffness, in patients 
with ankylosing spondylitis (AS). 
Methods: VO2peak was assessed by a maximal walking test on treadmill. Arterial stiffness was 
measured non-invasively (Sphygmocor apparatus). Cross-sectional associations between VO2peak 
and arterial stiffness were analysed using backwards multivariable linear regression. 
Results: Among 118 participating patients there were significant inverse associations between 
VO2peak and arterial stiffness independent of traditional CVD risk factors and measures of disease 
activity. 
Conclusion: Reduced CRF may be related to increased risk of CVD in AS.   
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Introduction 
Physical activity is a cornerstone of the treatment of ankylosing spondylitis (AS), and traditionally the 
focus has been on flexibility exercises. The majority of the AS patients reports to perform low 
intensity exercises (1;2), which does not improve cardiorespiratory fitness (CRF), and a study found 
that AS patients have lower CRF than controls (3).  
CRF is the circulatory and respiratory systems ability to supply oxygen to the skeletal muscles during 
sustained physical activity, and the most important lifestyle factor to improve CRF is physical activity 
at moderate to high intensity (4). CRF can be measured as maximum oxygen uptake (VO2peak) with 
gas-analyses during maximum exercise or estimated by indirect exercise-tests calculating VO2peak (3-
5). Low CRF is an independent predictor of cardiovascular disease (CVD) in the general population 
and in patient groups with increased risk of CVD such as diabetes (6), and improvement of CRF is 
associated with lower risk of CVD (4). Possibly, also in patients with AS, low CRF is a risk factor of 
CVD, however this has not been analysed previously. 
Patients with AS have an increased risk of CVD (7), and arterial stiffness, a validated marker of CVD 
risk (8), has been shown to be elevated in AS patients (9;10). In the general population, there is an 
inverse association between CRF and arterial stiffness (11;12). The hypothesis of this study was that 
there is an inverse relationship between CRF and arterial stiffness independent of traditional CVD risk 
factors and disease activity in AS patients.  
 
Methods 
This was a cross-sectional study in a cohort of patients with AS described previously (10). The study 
was approved by the local Committee of Ethics (approval number S-02059) and performed according 
to the Helsinki declaration. All patients gave their written consent. 
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Information on demographics, height at adulthood, medical history and medications was self-
reported in questionnaires, and later confirmed in an interview with a cardiologist. Body mass index 
(BMI) was calculated from measured height and weight. Loss of height was calculated as height at 
adulthood minus height at data collection. C-reactive protein (CRP), total cholesterol (TC) and high 
density lipoprotein cholesterol (HDL-c) were analysed consecutively. Disease activity was assessed by 
the AS Disease Activity Score (ASDAS)-CRP and by Bath AS Disease Activity Index (BASDAI) (13;14). 
CRF was estimated indirectly as VO2peak by a maximal walking test on a treadmill (modified Balke 
protocol) described previously (Supplementary file 1) (3). The test was ended when the participants 
were unable to increase inclination or speed of the treadmill and reported a perceived exertion on 
Borgs scale 17-20 (3).  
Brachial blood pressure (BP) and arterial stiffness were measured after at least 5 minutes of supine 
rest. Arterial stiffness was measured non-invasively (Sphygmocor apparatus) both as Augmentation 
Index (AIx) and Pulse Wave Velocity (PWV), described in detail previously (Supplementary file 1) (10). 
The statistical analyses were performed using SPSS version 21. Unadjusted associations between 
VO2peak and arterial stiffness were investigated in scatterplots with calculation of regression-lines.  
AIx and PWV were dependent variables in separate age and gender adjusted univariate linear 
regression analyses. We included the following independent variables: VO2peak, traditional CVD risk 
factors (smoking, BMI, TC, HDL-c and central mean arterial pressure), measures of inflammation and 
disease activity (CRP and ASDAS), use of non-steroidal anti-inflammatory drugs and other factors 
known to influence the arterial stiffness measurements (height in AIx analyses and loss of height in 
PWV analyses). PWV was log transformed to obtain normality of the residuals.  
We then performed backwards mulitivariable regression with variables with a p-value<0.25. Non-
significant variables (p-value≥0.05) were removed until only significant variables (p-value<0.05) 
remained. Non-significant variables from the adjusted univariate analyses were re-entered into the 
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final model to check for confounding. We assessed possible interactions between CRP and VO2peak 
as well as ASDAS and VO2peak. The residuals of the final models were assessed for normality. We 
also performed similar analyses excluding patients with established CVD.  
 
Results 
Out of 159 AS patients in the cohort, 118 patients had available data on both CRF and arterial 
stiffness. Missing data were mostly due to logistic reasons (Supplementary figure S1). Descriptive 
data are given in Table 1.  
Scatterplots (Figure 1) indicated inverse relations between VO2peak and both AIx (p<0.001) and PWV 
(p<0.001). In the multivariable linear regression models, VO2peak was independently and inversely 
associated with AIx (beta (95% confidence interval)) -0.3 (-0.6, -0.1), p=0.01 and lnPWV (-0.005 (-
0.010, -0.001)), p=0.03 (Table 2). There were no interactions between CRP and VO2peak or ASDAS 
and VO2peak. Analyses with exclusion of patients with established CVD (9 patients) did not alter 
results (data not shown).  
 
Discussion 
Our data demonstrate cross-sectional independent inverse associations between VO2peak (a 
measure of CRF) and arterial stiffness (a measure of CVD risk), assessed both as AIx and PWV in 
patients with AS. 
Although similar inverse relations between CRF and arterial stiffness have been found in the general 
population (11;12), we have not identified other studies analysing associations between CRF and 
arterial stiffness in patients with AS or other inflammatory joint diseases (IJD). In patients with 
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rheumatoid arthritis (RA) one study found inverse associations between increasing level of self-
reported physical activity and AIx, in line with our results (15). Another study on RA found that higher 
CRF was associated with a better CVD risk profile; however arterial stiffness was not an outcome 
(16). We have previously published results from a randomized controlled trial evaluating the effects 
of high intensity exercise in patients with AS showing significant treatment effects on both VO2peak 
(increased) and arterial stiffness (decreased), although, due to the low sample size, associations 
between the changes of these parameters were not evaluated (17). 
CRF is determined by genes, age, gender, physical activity, smoking, obesity and medical conditions, 
where physical activity is the most important lifestyle factor (4). In the general population there is a 
dose-response relation between physical activity and CRF where physical activity/exercise at 
moderate and high intensity results in improvement of CRF. Thus, CRF is a marker of habitual physical 
activity (4).  
The arterial stiffness is determined by the functional and structural properties of the arterial wall. 
Traditional CVD risk factors (hypertension, hypercholesterolemia, BMI and smoking) and IJD are 
associated with increased arterial stiffness (18). Moreover, regular aerobic high intensity exercise can 
reduce arterial stiffness in healthy adults and patients with increased risk of CVD (19). Regular 
aerobic exercise can affect both functional and structural components of the arterial wall, and 
approximately 40% of the CVD risk reduction of aerobic exercise is believed to be attributed to 
improved vascular hemodynamic properties, including arterial stiffness (8;19).  
Accordingly, regular exercises may be an important factor behind the associations between CRF and 
arterial stiffness measurements in the present study. In studies of the general population 
improvement of CRF (where the participants increased the amount of exercise), has been associated 
with lower risk of CVD (4). Therefore, high intensity exercises aiming at improving CRF, may be an 
attractable way to reduce arterial stiffness and CVD risk in patients with AS.  
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Our group has previously published results from the same AS cohort where disease-related 
complaints were barriers for physical activity (20), and disease activity (ASDAS) was inversely 
associated with CRF (3). Accordingly, high disease activity may result in less physical activity and 
reduced CRF which in turn is associated with increased risk of CVD. Reducing disease activity by 
optimal medical treatment may facilitate increased amount of exercise at intensities needed to 
increase CRF and thereby reducing CVD risk. 
There are some limitations of our study. This is a cross-sectional study, and the results are 
associations and cannot indicate causality. There may be bidirectional effects; high CRF may reduce 
the arterial stiffness by mechanisms mentioned previously, but increased arterial stiffness may also 
reduce CRF through increased systolic heart load, limiting cardiac output and thus reducing VO2peak 
(11). However, repeating the analyses after exclusion of patients with CVD did not alter the results, 
indicating that established CVD is not the only factor explaining the association between CRF and 
arterial stiffness. Ideally, VO2peak should have been measured by direct gas-analyses during a 
maximal exercise test. However, estimation of VO2peak by an indirect maximal exercise test is 
regarded as the second best test and is considered as an acceptable test of CRF in research. The 
validity has been tested by comparing the estimated with direct measurement of VO2peak (5). 
Estimation of VO2peak may be difficult in patients with physical disabilities, e.g. arthritis in joints of 
the lower limbs, and may result in underestimation of VO2peak. However, 98% of the patients 
reported reaching ≥17 on Borgs scale, indicating that the majority of patients exercised until 
exhaustion. Furthermore, the mean heart rate at the end of the exercise test (172 beats/minute) was 
close to the expected maximum heart rate (220 beats/minute minus age), which in this cohort is 171 
beats/minute, suggesting that VO2peak was not underestimated. Another important aspect is that 
we in the present study have analysed associations between biomarkers; VO2peak (marker of CRF), 
and arterial stiffness (marker of CVD risk). Biomarkers only mirror some aspects of the truth, and 
conclusions must be drawn with caution. Clinical cardiovascular endpoints would have been more 
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optimal endpoints, but would not be achievable this cohort with a mean age of 49 years and with a 
sample size of 118 patients. 
In conclusion, we found that low VO2peak was associated with higher arterial stiffness in patients 
with AS, indicating that low CRF is associated with increased CVD risk. The clinical implication of this 
association may be that CVD risk can be reduced by increasing CRF in patients with AS, but 
longitudinal intervention studies analysing the effect of exercises improving CRF upon CVD risk in AS 
are warranted. 
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Table 1 Descriptives of the patients 
Demographics  n=118 
Age (years), mean (SD)  48.9 (11.2) 
Gender (male), n (%) 75 (64) 
Current smoking, n (%) 18 (15) 
BMI (kg/m2), mean (SD) 25.6 (3.4) 
Height (cm), mean (SD) 174 (10) 
Loss of height (cm), median (IQR) 1 (0, 3) 
Disease characteristics  
BASDAI, mean (SD) 3.7 (1.8) 
ASDAS, mean (SD) 2.3 (0.9) 
CRP (mg/l), median (IQR) 3 (1, 9) 
Medication, current use  
NSAIDs, n (%) 77 (65) 
TNFα-inhibitors, n (%) 24 (20) 
Statins, n (%) 15 (13) 
Antihypertensives, n (%) 28 (24) 
Lipids  
TC (mmol/l), mean (SD)   5.4 (1.1) 
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HDL-c (mmol/l), mean (SD)   1.6 (0.5) 
Cardiorespiratory fitness   
VO2peak (ml/kg/min), mean (SD) 39.3 (8.0) 
Maximum heart rate (beats/min), mean (SD) 172 (19) 
Borgs scale ≥ 17 at end of exercise test, n (%) 115 (98) 
Hemodynamic  
Brachial SBP (mmHg), mean (SD) 127 (17) 
Brachial DBP (mmHg), mean (SD) 78 (10) 
CMAP (mmHg), mean (SD) 95 (12) 
AIx (%), mean (SD) 14.8 (13.1) 
PWV (m/s), median (IQR) 7.3 (6.2, 8.4) 
Ln(PWV+0.5), mean (SD) 1.986 (0.199) 
 
AIx, Augmentation Index; ASDAS, ankylosing spondylitis disease activity score; BMI, body mass index; 
CMAP, central mean arterial pressure; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-c 
high density lipoprotein cholesterol; IQR, interquartile range; NSAIDs, non-steroidal anti-
inflammatory drugs; PWV, pulse wave velocity; SBP, systolic blood pressure; SD, standard deviation; 
TC, total cholesterol; TNFα, tumor necrosis factor alpha; VO2peak; peak oxygen uptake. 
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Figure 1. Scatterplots cardiorespiratory fitness and arterial stiffness 
 
Associations between VO2peak and arterial stiffness measured as Augmentation Index and Pulse Wave Velocity with a regression line. 
VO2peak, peak oxygen uptake 
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Table 2 Associations between cardiorespiratory fitness and arterial stiffness, multivariable linear regression  
 
 
Outcome AIx Outcome lnPWV 
Univariate Multivariable Univariate Multivariable 
Beta (95%CI) p-value Beta (95%CI) p-value Beta (95%CI) p-value Beta (95%CI) p-value 
Age  0.8 (0.6, 0.9) <0.001 0.5 (0.3, 0.6) <0.001 0.012 (0.009, 0.014) <0.001 0.009 (0.006, 0.012) <0.001 
Gender (male) -12.5 (-16.9, -8.0) <0.001 -9.4 (-12.6, -6.2) <0.001 0.035 (-0.042, 0.113) 0.37 0.111 (0.046, 0.176) 0.001 
VO2peak (ml/kg/min) -0.4 (-0.6, -0.2)a 0.002 -0.3 (-0.6, -0.1) 0.01 -0.003 (-0.007, 0.002)a 0.24 -0.005 (-0.010, -0.001) 0.03 
Current smoking 0.7 (-3.6, 5.0)a 0.74   -0.072 (-0.147, 0.003)a 0.06   
BMI (kg/m2) 0.2 (-0.3, 0.6)a 0.44   0.007 (-0.001, 0.015)a 0.09   
CRP (mg/l) 0.1 (-0.1, 0.3)a 0.16   0.002 (-0.001, 0.005)a 0.28   
ASDAS 1.0 (-0.7, 2.7)a 0.25   0.010 (-0.022, 0.041)a 0.54   
NSAIDs 0.2 (-3.6, 3.1)a 0.89   -0.034 (-0.093, 0.026)a 0.26   
TC (mmol/l) 0.3 (-1.2, 1.8)a 0.67   0.032 (0.005, 0.059)a 0.02 0.028 (0.003, 0.053) 0.03 
HDL-c (mmol/l) -2.9 (-6.6, 0.8)a 0.12   -0.006 (-0.075, 0.063)a 0.86   
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CMAP (mmHg) 0.3 (0.2, 0.4)a <0.001 0.3 (0.1, 0.4) <0.001 0.006 (0.003, 0.008)a <0.001 0.004 (0.002, 0.007) 0.001 
Height (cm) -0.1 (-0.3, 0.1)a 0.18   NA NA   
Loss of height (cm) NA NA   -0.011 (-0.020, -0.002)a 0.02 -0.011 (-0.020, -0.002) 0.02 
R square   0.69    0.63  
Linear regression models with arterial stiffness as dependent variable. 
aadjusted age and gender 
AIx, Augmentation Index; ASDAS, ankylosing spondylitis disease activity score; BMI, body mass index; CMAP, central mean arterial pressure; CRP, C-reactive 
protein; HDL-c, high density lipoprotein cholesterol; NA, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; TC, total cholesterol; VO2peak, peak 
oxygen uptake. 
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Supplementary file 1 
Detailed information about estimation of cardiorespiratory fitness and arterial stiffness 
Cardiorespiratory fitness 
Cardiorespiratory fitness was assessed by indirect estimation of peak oxygen uptake (VO2peak). The 
patients performed a maximal exercise test on a treadmill where the exercise intensity was increased 
in a standardized manner by increased inclination and speed (according to a modified Balke protocol) 
until exhaustion (1). This is a validated test for estimating VO2peak according to the American College 
of Sports Medicine’s Guidelines for Exercise Testing and Prescriptions (2). 
Before the test, the patients had a five minute warm up walking on the treadmill. At the start of the 
test the treadmill speed was set at an individually adapted speed based on the heart rate during the 
warm up, usually at 4.8 km/h and with a 2.5% inclination. The heart rate was recorded during the 
test (Polar Sports Tester). Each cycle lasted for one minute, and at the end of the cycle the patient 
evaluated the degree of perceived exertion on Borgs scale (range 6-10, where 6-very, very light and 
20 - maximum exertion) (3). At the beginning of the test, the inclination was increased by 1.5% after 
every cycle and the speed was kept constant. When the patients reached an inclination of 15%, the 
speed was increased by 0.3 km/h by every cycle. The test was ended when the patient reported not 
being able to increase neither inclination nor speed and reported to be at 17-20 on Borgs scale. The 
maximum heart rate was recorded at the end of the test. 
The VO2peak was finally calculated by a formula given by the American College of Sports Medicine, 
from maximum speed (m/s) and inclination (%) by the end of the test, see textbox (4).  
 
  
 
 
Arterial stiffness 
Arterial stiffness was assessed both as pulse wave velocity (PWV) and augmentation index (AIx). The 
measurements were performed under similar and well defined conditions; the patients were fasting 
(except from water) and non-smoking for the last three hours and had not used alcohol for the last 
24 hours, the examinations were performed at the same time of the day in a quiet temperature-
controlled room after at least 5 minutes supine rest (5). The measurements were performed using 
Sphygmocor Apparatus (AtCor Medical, Australia), following recommendations from AtCor Medical. 
The PWV was measured as carotid femoral PWV which is considered as a golden standard 
measurement of the arterial stiffness (5). The PWV is a measure of the speed of the pulse wave, and 
was calculated my measuring the distance between the carotid pulse and the femoral pulse and the 
pulse transit time to these sites assessed by an electrocardiogram and pulse tonometry at the carotid 
and femoral artery. Finally, the PWV was calculated as distance divided by time, expressed in m/s. 
Graded walking (speeds ≤8.0 km/h): 
VO2 ml∙kg-1∙min-1 = (0.1∙ms-1+1.8∙ms-1∙inclination (%) +3.5) 
 
Graded running (speeds >8.0 km/h): 
VO2 ml∙kg-1∙min-1 = (0.2∙ms-1+0.9∙ms-1∙inclination (%) +3.5) 
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The AIx is a surrogate measure of arterial stiffness, and was assessed through pulse wave analyses 
(5). The shape of the pulse wave was recorded at the radial artery by tonometry, and the shape of 
the central pulse wave was estimated through a validated transfer factor. The pulse pressure of the 
central pulse wave is generated from a forward pressure from the heart and a backwards reflected 
pressure from the peripheral arteries. The difference between the pulse pressure and the forward 
pressure is defined as the augmented pressure. AIx was finally expressed by calculating the 
augmented pressure as a percentage of the pulse pressure.  
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Supplementary Figure S1.  Flowchart of the participants  
 
Some patients have missing data for multiple assessments. 
 
 
 
